¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Insulin Regular Human SubQ"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • insulin shock
    Àν¶¸°¼îÅ©
  • insulin-dependent
    Àν¶¸°ÀÇÁ¸-
  • insulin-dependent diabetes
    Àν¶¸°ÀÇÁ¸´ç´¢º´
  • insulin-induced hypoglycemia
    Àν¶¸°À¯µµÀúÇ÷´ç(Áõ)
  • insulin-like activity
    Àν¶¸°À¯»çȰ¼ºµµ
  • insulin-like growth factor
    Àν¶¸°À¯»ç¼ºÀåÀÎÀÚ
  • insulin-resistant diabetes
    Àν¶¸°ÀúÇ×´ç´¢º´
  • insulin-to-glucose ratio
    Àν¶¸°´ëÆ÷µµ´çºñ
  • intermediate-acting insulin
    Áß°£ÀÛ¿ëÀν¶¸°
  • long acting insulin
    Áö¼ÓÀÛ¿ëÀν¶¸°
  • non-insulin-dependent diabetes
    ºñÀν¶¸°ÀÇÁ¸´ç´¢º´
  • NPH insulin
    NPHÀν¶¸°
  • purified insulin
    ¼ø¼öÀν¶¸°, Á¤Á¦Àν¶¸°
  • suppressive insulin
    ¾ïÁ¦Àν¶¸°
  • short acting insulin
    ´Ü±âÀÛ¿ëÀν¶¸°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • human blood index
    »ç¶÷Ç÷¾×Áö¼ö
  • human immunodeficiency virus
    »ç¶÷¸é¿ª°áÇ̹ÙÀÌ·¯½º
  • human placental lactogen
    ŹÝÁ¥»ùÀÚ±ØÈ£¸£¸ó
  • human T-cell lymphotropic virus
    »ç¶÷Ƽ¼¼Æ÷¸²ÇÁģȭ¹ÙÀÌ·¯½º
  • crystalline insulin
    °áÁ¤Àν¶¸°
  • depot insulin
    ÀúÀåÀν¶¸°
  • insulin-dependent diabetes
    Àν¶¸°ÀÇÁ¸´ç´¢º´
  • insulin-resistant diabetes
    Àν¶¸°ÀúÇ×´ç´¢º´
  • non-insulin-dependent diabetes
    ºñÀν¶¸°ÀÇÁ¸´ç´¢º´
  • insulin-like growth factor
    Àν¶¸°À¯»ç¼ºÀåÀÎÀÚ
  • glucose insulin tolerance test
    Æ÷µµ´çÀν¶¸°°ßµõ°Ë»ç
  • insulin-induced hypoglycemia
    Àν¶¸°À¯µµÀúÇ÷´ç(Áõ)
  • insulin
    Àν¶¸°
  • insulin-dependent
    Àν¶¸°ÀÇÁ¸-
  • immunoreactive insulin
    ¸é¿ª¹ÝÀÀÀν¶¸°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • arginine-insulin test
    ¾Æ¸£±â´Ñ-Àν¶¸°½ÃÇè
  • globin insulin
    ±Û·ÎºóÀν¶¸°.
  • glucose insulin tolerance test =GITT
    Æ÷µµ´çÀν¶¸°ºÎÇϽÃÇè.
  • high purified insulin
    °í¼ø¼öÀν¶¸°.
  • immunoreactive insulin =IRI
    ¸é¿ª¹ÝÀÀ¼º(¡­Úãëëàõ) Àν¶¸°.
  • insulin receptor
    Àν¶¸°¼ö¿ëü(áôé»ô÷).
  • insulin receptor
    Àν¶¸°¼ö¿ëü.
  • insulin resistance
    Àν¶¸°ÀúÇ×¼º.
  • insulin secreting islet cell tumor
    Àν¶¸° ºÐºñ¼º µµ¼¼Æ÷Á¾¾ç.
  • insulin sensitivity
    Àν¶¸°°¨(¼ö)¼º.
  • insulin sensitivity index
    Àν¶¸°°¨¼ºÁö¼ö.
  • insulin sensitivity test
    Àν¶¸°°¨¼º½ÃÇè.
  • insulin shock
    Àν¶¸°¼ï.
  • insulin shock therapy
    Àν¶¸°¼ï¿ä¹ý.
  • insulin shock treatment
    Àν¶¸°Ãæ°ÝÄ¡·á.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • crystalline zinc insulin
    °áÁ¤¼º ¾Æ¿¬(Ì¿ïÜàõ䬿ç)Àν¶¸°.
  • depot insulin
    ÀúÀåÀν¶¸°.
  • diabetes mellitus,insulin deficiency
    Àν¶¸° °áÇÌÁõ(¡­ÌÀù¹ñø)
  • diabetes mellitus,insulin resistance
    Àν¶¸° ÀúÇ×(¼º)(¡­î½ù÷àõ)
  • diabetes mellitus,insulin-dependent
    Àν¶¸° ÀÇÁ¸¼º(¡­ëîðíàõ)
  • diabetes mellitus,non-insulin-dependent
    ºñ-Àν¶¸° ÀÇÁ¸¼º(Þª¡­)
  • globin insulin
    ±Û·ÎºóÀν¶¸°.
  • glucose insulin tolerance test =GITT
    Æ÷µµ´çÀν¶¸°ºÎÇϽÃÇè.
  • high purified insulin
    °í¼ø¼öÀν¶¸°.
  • immunoreactive insulin =IRI
    ¸é¿ª¹ÝÀÀ¼º(¡­Úãëëàõ) Àν¶¸°.
  • insulin
  • insulin antagonist
    Àν¶¸°±æÇ×ü.
  • insulin antagonist
    Àν¶¸°±æÇ×Á¦.
  • insulin antiserum
    Ç×Àν¶¸°Ç÷û.
  • insulin coma therapy
    Àν¶¸° È¥¼ö Ä¡·á
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lente insulin
    ·»Å×Àν¶¸°
  • NPH insulin
    NPH Àν¶¸°
  • protamine zinc insulin
    ÇÁ·ÎŸ¹Î ¾Æ¿¬(䬿ç) Àν¶¸°
  • suppressible insulin-like activity
    ¾ï¾Ð °¡´É(åääâʦÒö) Àν¶¸°À¯»çȰ¼º(×¾ÞÄüÀàõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NPH   1) Neutral Protamine Hagedorn Insulin
    = Isophane Insulin Susp...
AITT arginine insulin tolerance test; augmented insulin tolerance test
IRI immunoreactive insulin; insulin resistance index
IRS immunoreactive secretion; infrared spectrophotometry; insulin receptor species; insulin receptor sub...
IST inappropriate sinus tachycardia; insulin sensitivity test; insulin shock therapy; International Soci...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HI Human insulin
HIR Human insulin receptor
hIGF-I Human insulin-like growth factor I
rhIGF-I Recombinant human insulin-like growth factor I
rhIGF-1 Recombinant human insulin-like growth factor-1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • class I human leukocyte antigen
    Á¦ 1±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • class II human leukocyte antigen
    Á¦ 2±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • enteric cytopathogenic human orphan virus
    ¿¡ÄÚ ¹ÙÀÌ·¯½º
  • human bite
    »ç¶÷ ±³»ó
  • human chorionic gonadotropin
    »ç¶÷ À¶¸ð¼º ¼º¼± ÀÚ±Ø È£¸£¸ó
    ÀÌ´Â glyco
  • human counter
    Àü½Å °è¼ö ÀåÄ¡
    µ¿ÀǾî=whole body counter.
  • human ecology
    Àΰ£ »ýÅÂÇÐ, Àηù »ýÅÂÇÐ
    Àΰ£°ú ȯ°æ°úÀÇ »óÈ£ ÀÛ¿ëÀ» ¿¬±¸ÇÏ´Â »ý¹°ÇÐÀÇ ÇÑ ºÐ¾ß.
  • human fetal membrane
    »ç¶÷ ÅÂ¾Æ ¸·
  • human genome
    Àΰ£ °Ô³ð
  • human growth hormone
    ¼ºÀå È£¸£¸ó
    ¼ºÀåÀ» ÃËÁøÇÏ´Â ¹°ÁúÀ» ÃÑĪÇϸç, ƯÈ÷ ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â È£¸£¸óÀ» ¸»ÇÑ´Ù.
  • human histocompatibility antigen
    ÀÎü Á¶Á÷ ÀûÇÕ Ç׿ø
  • human immunodeficiency virus
    Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º
  • human immunodeficiency virus infection
    Àΰ£ ¸é¿ª °áÇÌ ¹ÙÀÌ·¯½º °¨¿°
  • human leukocyte antigen-B27
    ÀÎü ¹éÇ÷±¸ Ç×ü-B27
    º¸Åë °­Á÷¼º ôÃß¿° ȯÀÚ¿¡¼­ ³ªÅ¸³ª´Â À¯Àü Ç¥½ÃÀÚ.
  • human menopausal gonadotropin
    Æä°æ ¿©¼º ¼º¼± ÀÚ±Ø È£¸£¸ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
prompt insulin zinc suspension Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection.
Synonym: amorphous insulin zinc suspension, semilente insulin.
(05 Mar 2000)
protamine zinc insulin Insulin modified by the addition of protamine and zinc chloride; it contains 40 or 80 units per ml.
(05 Mar 2000)
semilente insulin Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection.
Synonym: amorphous insulin zinc suspension, semilente insulin.
(05 Mar 2000)
non-insulin-dependent diabetes mellitus <disease> An often mild form of diabetes mellitus of gradual onset, usually in obese individuals over age 35; absolute plasma insulin levels are normal to high, but relatively low in relation to plasma glucose levels; ketoacidosis is rare, but hyperosmolar coma can occur; responds well to dietary regulation and/or oral hypoglycaemic agents, but diabetic complications and degenerative changes can develop.
(05 Mar 2000)
nonsuppressible insulin-like activity A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity.
(12 Dec 1998)
NPH insulin isophane insulin
diabetes mellitus, insulin-dependent Diabetes mellitus characterised by insulin deficiency, sudden onset, severe hyperglycaemia, rapid progression to ketoacidosis, and death unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
(12 Dec 1998)
diabetes mellitus, non-insulin-dependent Diabetes characterised by the ability to survive without ketoacidosis in the absence of insulin therapy. It is usually of slow onset and patients exhibit a tendency to obesity.
(12 Dec 1998)
insulin <drug, growth factor, hormone> A polypeptide hormone (bovine insulin, 5780D) found in both vertebrates and invertebrates.
Secreted by the _ cells of the pancreas in response to high blood sugar levels, it induces hypoglycaemia. Defective secretion of insulin is the cause of diabetes mellitus. Insulin is also a mitogen, has sequence homologies with other growth factors and is a frequent addition to cell culture media for demanding cell types.
(18 Nov 1997)
insulin activating factor <chemical> Activates insulin gene transcription in pancreatic beta cells.
Synonym: insaf
(05 Dec 1998)
insulin allergy When a person's body has an allergic or bad reaction to taking insulin made from pork or beef or from bacteria, or because the insulin is not exactly the same as human insulin or because it has impurities. The allergy can be of two forms. Sometimes an area of skin becomes red and itchy around the place where the insulin is injected. This is called a local allergy. In another form, a person's whole body can have a bad reaction. This is called a systemic allergy. The person can have hives or red patches all over the body or may feel changes in the heart rate and in the rate of breathing. A doctor may treat this allergy by prescribing purified insulins or by desensitisation.
See: desensitisation.
(09 Oct 1997)
insulin antagonist Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it, therefore, glucagon is an antagonist of insulin.
(09 Oct 1997)
insulin-antagonizing factor A principle in extracts of the anterior lobe of the hypophysis that raises the blood sugar and antagonises the action of insulin; purified pituitary growth hormone produces an identical effect.
Synonym: insulin-antagonizing factor.
(05 Mar 2000)
insulin binding When insulin attaches itself to something else. This can occur in two ways. First, when a cell needs energy, insulin can bind with the outer part of the cell. The cell then can bring glucose (sugar) inside and use it for energy. With the help of insulin, the cell can do its work very well and very quickly. But sometimes the body acts against itself. In this second case, the insulin binds with antibodies. If the insulin is an injected form of insulin and not made by the body, the body sees the insulin as an outside or foreign substance. When the injected insulin binds with the antibodies, it does not work as well as when it binds directly to the cell.
(09 Oct 1997)
insulin coma treatment Rarely used treatment of major mental illness by means of hypoglycaemic coma induced by insulin.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Human Society
    µ¿¹° ¾ÖÈ£ Çùȸ;¼ö³­ ±¸Á¶È¸
  • human
    »ç¶÷ÀÇ;Àΰ£ÀûÀÎ;Àΰ£¿¡°Ô Àֱ⠽¬¿î
  • human document
    Àΰ£±â·Ï
  • human ecology
    Àΰ£ »ýÅÂÇÐ
  • human engineering
    Àΰ£°øÇÐ
  • human figure
    =Human One
  • human geography
    Àι®Áö¸®ÇÐ
  • human growth hormone
    Àΰ£¼ºÀå È£¸£¸ó(ÀÎüÀÇ ¼ºÀåÀ» Áö¹èÇÏ´Â ³úÇϼöü Á¾ÇÕ È£¸£¸ó)
  • human nature
    Àμº;Àΰ£¼º;ÀÎÁ¤
  • human potentials movement
    Àΰ£ ÀáÀç ´É·Â È¸º¹ ¿îµ¿(ÀÏÁ¾ÀÇ Áý´Ü ¿ä¹ýÀû ¼ö¾ç ¿îµ¿)
  • human power
    ÀÎÀû ÀÚ¿ø
  • human race
    Àηù 
  • human relations
    Àΰ£ °ü°è;´ëÀÎ °ü°è
  • human resource administration
    ÀÎÀû ÀÚ¿ø °ü¸®(Á¾¾÷¿øÀÇ °í¿ë,ÇØ°í,ºÒ¸¸ ó¸® µîÀÇ Àλç°ü¸®)
  • human rights
    (±âº»Àû)ÀαÇ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á